IP Verse

Rapamycin Derivative For Treating Advanced Solid Tumours

PatentPatent Analysis

EP3345602

NOVARTIS
Application Number
EP18155722A
Filing Date
Feb 18, 2002
Status
Granted And Under Opposition
Mar 4, 2022
Grant Date
Apr 6, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Biblio Summary

The patent EP3345602B1 was granted to Novartis on Apr 6, 2022 following the initial filing on Feb 18, 2002 under the application number EP18155722A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHYPHARMJan 6, 2023ADMISSIBLE
GENERICS UKJan 6, 2023WITHDRAWN
STADA ARZNEIMITTELJan 4, 2023WITHDRAWN

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents